Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | IKK16 | 2.0 | uM | Leptin | 1 | ng/mL | 3 | MIP-1A | 19.0 | 61 | |
RA2159 | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 17.0 | 55 | ||||
RA2159 | PD184352 | 0.1 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 19.0 | 81 | |
RA2159 | Lestaurtinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 19.0 | 89 | |
RA2159 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 19.0 | 56 | |
RA2159 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 19.0 | 83 | |
RA2159 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 21.0 | 94 | |
N2586 | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 20.0 | 66 | ||||
N2586 | PD184352 | 0.1 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 18.0 | 61 | |
N2586 | Lestaurtinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 21.5 | 68 | |
N2586 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 20.0 | 76 | |
N2586 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 19.0 | 78 | |
N2586 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | MIP-1A | 22.0 | 66 | |
RA2159 | IGF-I | 100 | ug/mL | 3 | MIP-1A | 17.0 | 73 | ||||
RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 17.0 | 73 | |
RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 17.0 | 56 | |
RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 18.0 | 75 | |
RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 19.0 | 57 | |
RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 21.0 | 45 | |
RA2159 | 3 | MIP-1A | 18.0 | 73 | |||||||
N2586 | IGF-I | 100 | ug/mL | 3 | MIP-1A | 18.0 | 75 | ||||
N2586 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 19.0 | 54 | |
N2586 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 15.0 | 71 | |
N2586 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 18.5 | 72 | |
N2586 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MIP-1A | 16.0 | 71 |